# Zoledronic Acid

## Aclasta inj 5mg/100mL

| 藥物代碼 | IACL |
| :--- | :--- |
| 適應症 | Treatment of Paget's disease of bone & postmenopausal osteoporosis . |
| 副作用 | Influenza, hypocalcemia, headache, lethargy, dyspnea, diarrhea, nausea, dyspepsia, bone pain, arthralgia, myalgia, flu-like symptoms, pyrexia, rigors, fatigue, pain, asthenia. Local site reactions. Osteonecrosis of the jaw.Cardiovascular: Peripheral edema \(Paget's Disease, 3%; osteoporosis, 4.6% to 5.5%; bone metastasis, 21% \)Endocrine metabolic: Weight decreased \(bone metastasis, 16% \)Gastrointestinal: Abdominal pain \(osteoporosis \(female\), 0.9% to 4.6%; osteoporosis \(male\), 7.9%; Paget's disease, 2%; hypercalcemia of malignancy, 16%; bone metastasis, 14% \), Constipation \(Paget's disease, 6%; hypercalcemia of malignancy, 27%; bone metastasis, 31% \), Diarrhea \(osteoporosis, 5.2% to 6%; Paget's disease, 6%; hypercalcemia of malignancy, 17%; bone metastasis, 24% \), Loss of appetite \(osteoporosis, 1% to 2%; Paget's disease, 2%; hypercalcemia of malignancy, 9%; bone metastasis, 22% \), Nausea \(osteoporosis, 4.5% to 8.5%; Paget's disease, 9%; hypercalcemia of malignancy, 29%; bone metastasis, 46% \), Vomiting \(Paget's disease, 2%; osteoporosis, 3.4% to 4.6%; hypercalcemia of malignancy, 14%; bone metastasis, 32% \)Musculoskeletal: Arthralgia \(osteoporosis \(female\), 17.9% to 23.8%; osteoporosis \(male\), 11.1%; hypercalcemia of malignancy, 5% to less than 10%; Paget's disease, 9%; bone metastasis, 21% \), Backache \(Paget's disease, 4%; bone metastasis, 15% \)Neurologic: Asthenia \(osteoporosis, 3.2 to 5.3%; Paget's disease, 2%; bone metastasis, 24% \), Dizziness \(osteoporosis, 2% to 7.6%; Paget's disease, 9%; bone metastasis, 18% \), Headache \(osteoporosis \(female\), 3.9% to 12.4%; osteoporosis \(male\), 15%; Paget's disease, 11%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 19% \), Insomnia \(hypercalcemia of malignancy, 15%; bone metastasis, 16% \), Paresthesia \(Paget's disease, 2%; bone metastasis, 15% .\)Renal: Nephrotoxicity \(bone metastasis, 11% to 17% \)Other: Fatigue \(osteoporosis \(female\), 2.1% to 5.4%; osteoporosis \(male\), 17.6%; Paget's disease, 8%; bone metastasis, 39% \), Fever \(osteoporosis \(female\), 7% to 18%; osteoporosis \(male\), 15.7%; Paget's disease, 3% to 11%; hypercalcemia of malignancy, 44%; bone metastasis, 32% \) |
| 禁忌 | Hypocalcemia. Pregnancy & lactation. Severe renal impairment. |
| 藥物保存方式 | N/A |
| 用法用量 | Paget's bone disease 5 mg as a single 15-min IV infusion with recommended daily allowance of supplemental Ca & vit D.during the initial 2 weeks following administration. Postmenopausal osteoporosis 5 mg once a year as a single 15-min IV infusion. Supplement with Ca 1200 mg & vit D 400-800 iu daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest moderate risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 輸注時間 &gt; 15min |
| 注意事項 | 1.注射液不可接觸含有鈣離子或其他二價離子的溶液 \(例如：lactated Ringer\)，必須以單獨的輸注管路給藥。在靜脈輸注完畢後，應以10mL N/S 沖洗靜脈管路。 2.若藥品已冷藏，輸注前先讓注射溶液回復到室溫。開瓶後的溶液在攝氏2-8度下可保存24小時。 3.病人接受Aclasta輸注前，必須保持水分充足的狀態\(adequately hydrated\)。 |

## Bolenic IV infusion 4mg

| 藥物代碼 | IBOL |
| :--- | :--- |
| 適應症 | Prevention of skeletal related events \(pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia\) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy \(HCM\). |
| 副作用 | Very common: Hypophosphatemia. Common: Anemia, headache, conjunctivitis, nausea, vomiting, anorexia, bone pain, myalgia, arthralgia, renal impairment, fever, flu-like syndrome, blood creatinine & blood urea increase, hypocalcemia.Cardiovascular: Peripheral edema \(Paget's Disease, 3%; osteoporosis, 4.6% to 5.5%; bone metastasis, 21% \)Endocrine metabolic: Weight decreased \(bone metastasis, 16% \)Gastrointestinal: Abdominal pain \(osteoporosis \(female\), 0.9% to 4.6%; osteoporosis \(male\), 7.9%; Paget's disease, 2%; hypercalcemia of malignancy, 16%; bone metastasis, 14% \), Constipation \(Paget's disease, 6%; hypercalcemia of malignancy, 27%; bone metastasis, 31% \), Diarrhea \(osteoporosis, 5.2% to 6%; Paget's disease, 6%; hypercalcemia of malignancy, 17%; bone metastasis, 24% \), Loss of appetite \(osteoporosis, 1% to 2%; Paget's disease, 2%; hypercalcemia of malignancy, 9%; bone metastasis, 22% \), Nausea \(osteoporosis, 4.5% to 8.5%; Paget's disease, 9%; hypercalcemia of malignancy, 29%; bone metastasis, 46% \), Vomiting \(Paget's disease, 2%; osteoporosis, 3.4% to 4.6%; hypercalcemia of malignancy, 14%; bone metastasis, 32% \)Musculoskeletal: Arthralgia \(osteoporosis \(female\), 17.9% to 23.8%; osteoporosis \(male\), 11.1%; hypercalcemia of malignancy, 5% to less than 10%; Paget's disease, 9%; bone metastasis, 21% \), Backache \(Paget's disease, 4%; bone metastasis, 15% \)Neurologic: Asthenia \(osteoporosis, 3.2 to 5.3%; Paget's disease, 2%; bone metastasis, 24% \), Dizziness \(osteoporosis, 2% to 7.6%; Paget's disease, 9%; bone metastasis, 18% \), Headache \(osteoporosis \(female\), 3.9% to 12.4%; osteoporosis \(male\), 15%; Paget's disease, 11%; hypercalcemia of malignancy, 5% to less than 10%; bone metastasis, 19% \), Insomnia \(hypercalcemia of malignancy, 15%; bone metastasis, 16% \), Paresthesia \(Paget's disease, 2%; bone metastasis, 15% .\)Renal: Nephrotoxicity \(bone metastasis, 11% to 17% \)Other: Fatigue \(osteoporosis \(female\), 2.1% to 5.4%; osteoporosis \(male\), 17.6%; Paget's disease, 8%; bone metastasis, 39% \), Fever \(osteoporosis \(female\), 7% to 18%; osteoporosis \(male\), 15.7%; Paget's disease, 3% to 11%; hypercalcemia of malignancy, 44%; bone metastasis, 32% \) |
| 禁忌 | Known hypersensitivity to zoledronic acid or other bisphosphonates. |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest moderate risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | Micromedex Lactation Rating: Infant risk cannot be ruled out. a\) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2\) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However, as zoledronic acid binds to bone long-term, it is recommended that it should not be administered to a nursing woman. |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | 5mL注射用水稀釋 |
| 輸注點滴液 | 【D5W】 可選  【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | 加入100mL相容輸注液中輸注，IVD &gt; 15 mins，不可使用含鈣或兩價陽離子的溶液 |
| 注意事項 | 1. patients should be adequately hydrated prior to administration 2. If previously refrigerated, allow solution to reach room temperature before administration 3. administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes, over a constant infusion rate 4. Do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions \(eg, lactated Ringer\) |

